Valneva vaccine neutralises Omicron variant
French-Austrian vaccine specialist Valneva SE has demonstrated that its COVID-19 vaccine induced neutralisation of 87% of the Omicron variant.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1997 entries already.
Entries by Thomas Gabrielczyk
Beckman Coulter receives IVDR certification covering more than 200 flow cytometry reagents
Leading the way with the industrys largest portfolio of CE-IVD labeled flow cytometry reagents in the market, Beckman Coulter Life Sciences announces that it has received a EU Quality Management System Certificate under the new In Vitro Diagnostic Medical Devices Regulation (IVDR) for more than 200 flow cytometry reagents developed and manufactured at their Marseille, France facility.
Neurimmune expands drug discovery collaboration with Ono Pharmaceutical
Swiss Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. covering antibody drug targeting neurodegenerative diseases
Evotec and Lilly to collaborate in metabolic diseases
German Evotec SE has entered into a US$1bn drug discovery and development partnership with Eli Lilly and Company in the field of metabolic and renal diseases and diabetes.
Protagen, BioAnalytix and GeneWerk launch ProtaGene
Following their last year announcement to merge, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH launch a CRO named ProtaGene.
BioNTech SE licences Cresendo Bios Humabody technology
BioNTech and Crescendo Biologics have signed a US-$790m deal to develop multi-specific precision immunotherapies .
Novartis AG executes licence option with Molecular Partners
After Molecular Partners AG reported an 78% reduction of hospitalisation by a single ensovibep dose in infected COVID-19 patients, Novartis AG is to pay a CHF150m milestone.
Neurimmune inks US-$760 deal with AstraZeneca
Neurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006.
Santhera finds Chinese marketing partner for vamorolone
Swiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone.
DNA Script bags US$200m financing
Moderna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.